Hey BTB,
Glad you had a listen. It was interesting & gives some insight from the perspective of senior researchers.
I don’t think it’s a “green light” issue in India from Ethics or Regulatory Bodies for CLARITY 2.0. I know it’s frustrating, because treating earlier may help keep people out of hospital & becoming very unwell. Totally seperate from REMAP-CAP, but via The George Institute & NHMRC so it is all legitimate & globally respected principal investigators.
The work already done with REMAP-CAP & other large trials like RECOVERY have already made a big difference in treating patients with COVID-19, but a lot more to go to improve treatment guidelines.
GLTAH
Hey BTB, Glad you had a listen. It was interesting & gives some...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
-0.020(4.60%) |
Mkt cap ! $228.5M | |||
| Open | High | Low | Value | Volume |
| 43.5¢ | 43.5¢ | 41.0¢ | $731.5K | 1.748M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 269178 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 14070 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |